The annual costs associated with human papillomavirus types 6, 11, 16, and 18 infections in Finland

Scandinavian Journal of Infectious Diseases

Volumn 43, Issue 3, 2011, Pages 209-215

  Herse, Fredrik ^a   Reissell, Eeva ^a  

^a Nordic Healthcare Group   (Finland)

Author keywords

cervical cancers; costs; genital warts; HPV infection

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CERVICAL INTRAEPITHELIAL NEOPLASTIC LESION 1; CERVICAL INTRAEPITHELIAL NEOPLASTIC LESION 2; CERVICAL INTRAEPITHELIAL NEOPLASTIC LESION 3; CHILD; CONDYLOMA ACUMINATUM; DISEASE REGISTRY; EQUIVOCAL CYTOLOGICAL ABNORMALITY; FEMALE; FINLAND; HEALTH CARE COST; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; INFANT; MAJOR CLINICAL STUDY; NONHUMAN; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX CANCER; UTERINE CERVIX DISEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHILD; CONDYLOMATA ACUMINATA; FEMALE; FINLAND; HEALTH CARE COSTS; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; YOUNG ADULT;

EID: 79951604014     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2010.541492     Document Type: Article

References (17)

1. Barr E, Sings HL. Prophylactic HPV vaccines: new interventions for cancer control. Vaccine 2008;26:6244-57.
2. Kahn JA. HPV vaccination for the prevention of cervical intraepithelial neoplasia. N Engl J Med 2009;361: 271-8.
3. Syrj än en KJ. Annual disease burden due to human papillomavirus 16 and 18 infections in Finland. Scand J Infect Dis Suppl 2009;108:2-32.
4. Annemans L, Ré my V, Lamure E, Spaepen E, Lamotte M, Muchada JP, Largeron N. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium. J Med Econ 2008;11: 135-50. (Pubitemid 351613819)
5. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007;13:28-41. (Pubitemid 46057835)
6. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928-43. (Pubitemid 46740303)
7. Hiltunen-Back E. Kondylooman hoito. Duodecim 2008;124: 1121-5.
8. Lacey C, Lowndes C, Shah K. HPV vaccines and screening in the prevention of cervical cancer. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006;24(Suppl 3):S35-S41. (Pubitemid 44293033)
9. Hujanen T, Kapiainen S, Tuominen U, Pekurinen M. Terveydenhuollon yksikk ö kustannukset Suomessa vuonna 2006. THL Ty ö papereita 3/2008. Helsinki: National Institute for Health and Welfare; 2008.
10. Monto K, Nieminen P. Gynekologisten irtosolunä ytteiden määrä tjaraportointitavat Suomessa. Suomen Lä ä kä rilehti 2005;18-19:2093-6.
11. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998;13:1-7.
12. Insinga Ralph P. Annual productivity costs due to cervical cancer mortality in the United States, Women's Health Issues, 2006;16(5):236-242.
13. Annemans L, Ré my V, Oyee J, Largeron N. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium. Pharmacoeconomics 2009;27:231-45.
14. Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol 2004;191:114-20. (Pubitemid 39077963)
15. Paavonen J. Mit ä HPV-rokotteilta voidaan odottaa? Suomen L ää kä rilehti 2009;11:1017-21.
16. Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009;85:499-502.
17. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LA. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008;14:244-51. (Pubitemid 351213674)